Wells Fargo’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Wells Fargo’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3	Closed	–	–	7139
2024 Q2	$0	Sell	3 -1	-25%	–	﹤0.01%	7632
2024 Q1	$0	Buy	+4	New	–	﹤0.01%	7753
2023 Q2	–	Sell	-200	Closed	-$36	–	7731
2023 Q1	$36	Hold	200	–	–	﹤0.01%	7198
2022 Q4	$40	Hold	200	–	–	﹤0.01%	7086
2022 Q3	$0	Hold	200	–	–	﹤0.01%	7590
2022 Q2	$0	Sell	200 -40	-17%	-$25	﹤0.01%	7701
2022 Q1	$0	Hold	240	–	–	﹤0.01%	8034
2021 Q4	$1K	Sell	240 -60	-20%	-$194	﹤0.01%	7103
2021 Q3	$1K	Buy	+300	New	+$1.07K	﹤0.01%	6832

Other funds holding DNA.WS

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

HIA

Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Wells Fargo's DNA.WS Position: Q3 2024 in Review

Wells Fargo sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q3 2024, closing a stake of 3 shares.

Wells Fargo first reported a position in DNA.WS in Q3 2021 and held it in 9 quarters. The position peaked at $1K in Q4 2021. 5 funds tracked by Wall St. Rank hold DNA.WS as of Q3 2024.

Wells Fargo reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q3 2024 after selling out during the quarter.
Wells Fargo sold 3 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q3 2024.
Wells Fargo first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 9 quarters.
Wells Fargo's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $1K in Q4 2021.
5 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q3 2024.

Based on Wells Fargo's 13F filing for Q3 2024, filed 13 Nov 2024.